Citations

Clear

479 citation(s) found for "Tobias, JS".

0468 CRASH: Cancer Reoccurrence Is Accelerated by Episodic Hypoxemia
Rodriguez, Fernando Figueroa , Peikert, Tobias, Escalante, Patricio , Lim, Kaiser G. , Morgenthaler, Timothy I.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A201-A202

10.1093/sleep/zsae067.0468 Get It

Abstract Introduction Several studies have shown a positive association between Obstructive Sleep Apnea (OSA) and malignancies such as lung cancer. However, the effects of intermittent hypoxemia in cancer-free survival following curative therapy are not known. We propose that OSA-related episodic hypoxemia and hypoxic burden are independent risk factors for accelerated lung cancer reoccurrence (< 2 years). Methods We performed a retrospective record review of patients 18 years and older from January 2016 to September 2023 with history of non-small cell lung cancer who received an overnight oximetry study (OXY) within three years prior to undergoing curative malignancy treatment. Subjects with history of central sleep apnea, baseline oxygen saturation (SpO2) below 90%, receiving supplemental oxygen or treatment for OSA were excluded. Results 403 patients met inclusion criteria (52% female vs 48% males; median age 74 y). The most common histologic subtypes were adenocarcinoma (68%) followed by squamous cell carcinoma (22%). Most patients fell into Stage IA1 (35%) followed by IA2 (24.1%) and IB (19%) as per TNM 8th edition classification. Over this period, 68 patients (22%) had lung cancer recurrence (median 19 months). A 4% oxygen desaturation index (ODI) of >15 and time spent in desaturation events were found to be a risk factor for cancer reappearance in less than 2 years (p< 0.001). Measures of hypoxic burden such as time spent below 89% SpO2, average SpO2 value below 89%, and single nadir oxygen levels, showed a similar association (p< 0.001). This was irrespective of histologic subtype, stage at diagnosis, and all studied demographic variables. Basal SpO2 demonstrated no correlation. A multivariate proportional hazard survival model showed that ODI>15 was no longer significant, however average SpO2 below 89% and single minimum oxygen level remained strongly correlated with accelerated recurrence. Conclusion This study showed a strong, positive association between accelerated lung cancer recurrence and OSA-related episodic hypoxemia and hypoxic burden on our univariate analysis. The multivariate model demonstrated correlation with hypoxic load measures only, suggesting the need for a larger sample to elucidate the involvement of this highly treatable risk factor. To our knowledge, this is the first study revealing this potential link. Support (if any)
Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma
Breitenecker, Kristina , Heiden, Denise, Demmer, Tobias, Weber, Gerhard, Primorac, Ana-Maria, Hedrich, Viola , Ortmayr, Gregor , Gruenberger, Thomas , Herndler‐Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Herndler-Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Gruenberger, Thomas , Weber, Gerhard, Starlinger, Patrick

Mayo Clinic

International Journal of Molecular Sciences | April 11, 2024 | Volume: 25 | Issue: 8 | Pages: 4202

10.3390/ijms25084202 | PMID 38673795 Get It

The activation of the receptor tyrosine kinase Axl by Gas6 is a major driver of tumorigenesis. Despite recent insights, tumor cell-intrinsic and -extrinsic Axl functions are poorly understood in hepatocellular carcinoma (HCC). Thus, we analyzed the cell-specific aspects of Axl in liver cancer cells and in the tumor microenvironment. We show that tumor-intrinsic Axl expression decreased the survival of mice and elevated the number of pulmonary metastases in a model of resection-based tumor recurrence. Axl expression increased the invasion of hepatospheres by the activation of Akt signaling and a partial epithelial-to-mesenchymal transition (EMT). However, the liver tumor burden of Axl+/+ mice induced by diethylnitrosamine plus carbon tetrachloride was reduced compared to systemic Axl−/− mice. Tumors of Axl+/+ mice were highly infiltrated with cytotoxic cells, suggesting a key immune-modulatory role of Axl. Interestingly, hepatocyte-specific Axl deficiency did not alter T cell infiltration, indicating that these changes are independent of tumor cell-intrinsic Axl. In this context, we observed an upregulation of multiple chemokines in Axl+/+ compared to Axl−/− tumors, correlating with HCC patient data. In line with this, Axl is associated with a cytotoxic immune signature in HCC patients. Together these data show that tumor-intrinsic Axl expression fosters progression, while tumor-extrinsic Axl expression shapes an inflammatory microenvironment.
Evaluation of automated airway morphological quantification for assessing fibrosing lung disease
Pakzad, Ashkan , Cheung, WK., Moorsel, CHM. Van, Quan, Ke, Bartholmai, Brian J. , Es, HW. Van, Ezircan, A., Beek, F. Van, Veltkamp, Marcel , Karwoski, R., Peikert, Tobias, Clay, RD., Foley, Finbar, Braun, Christian, Sudre, Carole H. , Alexander, Daniel C. , Wijeratne, P. A. , Hawkes, David J. , Hurst, John R. , Jacob, Joseph , Bartholmai, Brian J , Cheung, Wing Keung , Quan, K., Moğulkoç, Nesrin , Clay, Ryan , Savaş, Recep , Doel, Tom , Hu, Y.

Mayo Clinic

Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization | March 31, 2024 | Volume: 12 | Issue: 1 | Pages: No page available

10.1080/21681163.2024.2325361 Get It

Influence of artificial intelligence on the diagnostic performance of endoscopists in the assessment of Barrett’s esophagus: a tandem randomized and video trial
Meinikheim, M. , Mendel, Robert , Scheppach, Markus W. , Nagl, Sandra , Schnoy, Elisabeth , Römmele, Christoph , Schulz, Dominik , Schlottmann, J., Prinz, Friederike, Rauber, David , Rückert, Tobias, Parsa, Nasim , Messmann, Helmut , Ebigbo, Alanna , Meinikheim, Michael , Römmele, Christoph , Matsumura, Tomoaki , Palm, Christoph , Probst, Andreas , Muzalyova, Anna , Fernández‐Esparrach, Glòria , Byrne, Michael F.

Mayo Clinic

Endoscopy | March 29, 2024 | Volume: 56 | Issue: 09 | Pages: 641-649

10.1055/a-2296-5696 | PMID 38547927 Get It

Abstract Background This study evaluated the effect of an artificial intelligence (AI)-based clinical decision support system on the performance and diagnostic confidence of endoscopists in their assessment of Barrett’s esophagus (BE). Methods 96 standardized endoscopy videos were assessed by 22 endoscopists with varying degrees of BE experience from 12 centers. Assessment was randomized into two video sets: group A (review first without AI and second with AI) and group B (review first with AI and second without AI). Endoscopists were required to evaluate each video for the presence of Barrett’s esophagus-related neoplasia (BERN) and then decide on a spot for a targeted biopsy. After the second assessment, they were allowed to change their clinical decision and confidence level. Results AI had a stand-alone sensitivity, specificity, and accuracy of 92.2%, 68.9%, and 81.3%, respectively. Without AI, BE experts had an overall sensitivity, specificity, and accuracy of 83.3%, 58.1%, and 71.5%, respectively. With AI, BE nonexperts showed a significant improvement in sensitivity and specificity when videos were assessed a second time with AI (sensitivity 69.8% [95%CI 65.2%–74.2%] to 78.0% [95%CI 74.0%–82.0%]; specificity 67.3% [95%CI 62.5%–72.2%] to 72.7% [95%CI 68.2%–77.3%]). In addition, the diagnostic confidence of BE nonexperts improved significantly with AI. Conclusion BE nonexperts benefitted significantly from additional AI. BE experts and nonexperts remained significantly below the stand-alone performance of AI, suggesting that there may be other factors influencing endoscopists’ decisions to follow or discard AI advice.
Cosmetic penile enhancement procedures: an SMSNA position statement
Trost, Landon , Khera, Mohit, Köhler, Tobias, Bernie, Helen L, Jenkins, Lawrence, Watter, Daniel N, Yafi, Faysal A, Ziegelmann, Matthew, Carrier, Serge , Jenkins, Lawrence C. , Jenkins, Lawrence , Khera, Mohit, Köhler, Tobias, Bernie, Helen L, Jenkins, Lawrence, Watter, Daniel N, Yafi, Faysal A, Ziegelmann, Matthew

Mayo Clinic

The Journal of Sexual Medicine | March 26, 2024 | Volume: 21 | Issue: 6 | Pages: 573-578

10.1093/jsxmed/qdae045 | PMID 38654638 Get It

Abstract Background Penile cosmetic enhancement procedures have been performed for many years with varying success. However, they have historically been relegated to niche areas of sexual medicine, with limited data, and have not achieved mainstream adoption. More recently, the topic has been increasingly discussed within academic congresses due to availability of novel techniques, therapies, and procedures. Given their distinctive nature, the Sexual Medicine Society of North America (SMSNA) felt that it was pertinent to develop formal position statements to help guide both patients and sexual medicine providers on the current state of the scientific literature and to give recommendations for future research. Aim The study sought to provide an evidence-based set of recommendations for injection and surgical procedures designed to lengthen, augment, or otherwise cosmetically enhance the penis. Methods A review was performed of all scientific literature listed in PubMed from inception through December 2023 relating to penile cosmetic enhancement procedures. Only invasive (injection/surgery) therapies were included due to their distinct risk-benefit profile compared with more conservative treatments (eg, vacuum erection devices, penile traction devices). Similar therapies were categorized, with pertinent data summarized and used to help create relevant position statements. All statements were expert opinion only and were based on analyses of the potential risks and benefits of the specific therapies. Outcomes A total of 6 position statements were issued relating to 5 distinct sexual medicine cosmetic enhancement procedures. Results A consensus opinion was reached by SMSNA leadership on the state of injection/surgical penile cosmetic enhancement procedures as of 2024. Key topic areas addressed included injectable soft tissue fillers, suspensory ligament division, graft-and-flap procedures, silicone sleeve implants, and sliding/slicing techniques. Distinct recommendations were tailored to each therapy and were based solely on the current state of the literature. It is anticipated that future studies will further inform position statements and will lead to ongoing modifications. Clinical Implications The current position statements provide both patients and clinicians evidence-based, expert recommendations on best practices relating to penile cosmetic enhancement procedures. Strengths and Limitations Strengths include the use of an expert panel of sexual medicine clinicians, consensus design, and summary of existing literature. Limitations include expert opinion and limited research on the topic. Conclusion The current SMSNA position statements provide evidence-based, consensus opinions on the appropriate role for penile augmentation and cosmetic procedures in 2024.
Premorbid body weight predicts weight loss in both anorexia nervosa and atypical anorexia nervosa: Further support for a single underlying disorder
Hebebrand, Johannes , Seitz, Jochen , Föcker, Manuel , Viersen, Hanna Preuss‐van , Huß, Michael , Bühren, Katharina , Dahmen, Brigitte , Becker, Katja , Weber, Linda , Jaite, Charlotte , Romanos, Marcel , Seidel, Maria , Fleischhaker, Christian , Möhler, Eva , Hahn, Freia , Hagmann, Daniela , Renner, Tobias , Schulze, Ulrike , Thiemann, Ulf , Antony, Gisela , Matthews, Abigail , Peters, Triinu , Correll, Christoph Ulrich , Jaite, Charlotte , Egberts, Karin , Romanos, Marcel , Ehrlich, Stefan , Seidel, Maria , Roessner, Veit , Fleischhaker, Christian , Möhler, Eva , Hahn, Freia , Kaess, Michael , Legenbauer, Tanja , Hagmann, Daniela , Renner, Tobias J , Schulze, Ulrike M E , Thiemann, Ulf , Wessing, Ida , Antony, Gisela , Herpertz-Dahlmann, Beate , Matthews, Abigail , Peters, Triinu , Viersen, Hanna Preuss‐van , Egberts, Karin , Ehrlich, Stefan

Mayo Clinic

International Journal of Eating Disorders | March 26, 2024 | Volume: 57 | Issue: 4 | Pages: 967-982

10.1002/eat.24189 | PMID 38528714 Get It

Abstract Objective For adolescents, DSM‐5 differentiates anorexia nervosa (AN) and atypical AN with the 5th BMI‐centile‐for‐age. We hypothesized that the diagnostic weight cut‐off yields (i) lower weight loss in atypical AN and (ii) discrepant premorbid BMI distributions between the two disorders. Prior studies demonstrate that premorbid BMI predicts admission BMI and weight loss in patients with AN. We explore these relationships in atypical AN. Method Based on admission BMI‐centile < or ≥5th, participants included 411 female adolescent inpatients with AN and 49 with atypical AN from our registry study. Regression analysis and t ‐tests statistically addressed our hypotheses and exploratory correlation analyses compared interrelationships between weight loss, admission BMI, and premorbid BMI in both disorders. Results Weight loss in atypical AN was 5.6 kg lower than in AN upon adjustment for admission age, admission height, premorbid weight and duration of illness. Premorbid BMI‐standard deviation scores differed by almost one between both disorders. Premorbid BMI and weight loss were strongly correlated in both AN and atypical AN. Discussion Whereas the weight cut‐off induces discrepancies in premorbid weight and adjusted weight loss, AN and atypical AN overall share strong weight‐specific interrelationships that merit etiological consideration. Epidemiological and genetic associations between AN and low body weight may reflect a skewed premorbid BMI distribution. In combination with prior findings for similar psychological and medical characteristics in AN and atypical AN, our findings support a homogenous illness conceptualization. We propose that diagnostic subcategorization based on premorbid BMI, rather than admission BMI, may improve clinical validity. Public significance Because body weights of patients with AN must drop below the 5th BMI‐centile per DSM‐5, they will inherently require greater weight loss than their counterparts with atypical AN of the same sex, age, height and premorbid weight. Indeed, patients with atypical AN had a 5.6 kg lower weight loss after controlling for these variables. In comparison to the reference population, we found a lower and higher mean premorbid weight in patients with AN and atypical AN, respectively. Considering previous psychological and medical comparisons showing little differences between AN and atypical AN, we view a single disorder as the most parsimonious explanation. Etiological models need to particularly account for the strong relationship between weight loss and premorbid body weight.
Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: A systematic review and meta‐analysis
Hagbohm, Caroline , Jónsson, Dagur Ingi , Banwell, Brenda , Wickström, Ronny , Ineichen, Benjamin Victor , Flanagan, E P , Ineichen, Benjamin V , Ouellette, Russell , Flanagan, Eoin P. , Piehl, Fredrik , Iacobaeus, Ellen , Granberg, Tobias

Mayo Clinic

European Journal of Neurology | March 20, 2024 | Volume: 31 | Issue: 7 | Pages: No page available

10.1111/ene.16284 | PMID 38506182 Get It

Abstract Objective This study was undertaken to provide a comprehensive review of neuroimaging characteristics and corresponding clinical phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy (GFAP‐A), a rare but severe neuroinflammatory disorder, to facilitate early diagnosis and appropriate treatment. Methods A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analysis)‐conforming systematic review and meta‐analysis was performed on all available data from January 2016 to June 2023. Clinical and neuroimaging phenotypes were extracted for both adult and paediatric forms. Results A total of 93 studies with 681 cases (55% males; median age = 46, range = 1–103 years) were included. Of these, 13 studies with a total of 535 cases were eligible for the meta‐analysis. Clinically, GFAP‐A was often preceded by a viral prodromal state (45% of cases) and manifested as meningitis, encephalitis, and/or myelitis. The most common symptoms were headache, fever, and movement disturbances. Coexisting autoantibodies (45%) and neoplasms (18%) were relatively frequent. Corticosteroid treatment resulted in partial/complete remission in a majority of cases (83%). Neuroimaging often revealed T2/fluid‐attenuated inversion recovery (FLAIR) hyperintensities (74%) as well as perivascular (45%) and/or leptomeningeal (30%) enhancement. Spinal cord abnormalities were also frequent (49%), most commonly manifesting as longitudinally extensive myelitis. There were 88 paediatric cases; they had less prominent neuroimaging findings with lower frequencies of both T2/FLAIR hyperintensities (38%) and contrast enhancement (19%). Conclusions This systematic review and meta‐analysis provide high‐level evidence for clinical and imaging phenotypes of GFAP‐A, which will benefit the identification and clinical workup of suspected cases. Differential diagnostic cues to distinguish GFAP‐A from common clinical and imaging mimics are provided as well as suitable magnetic resonance imaging protocol recommendations.
European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency
Beuschlein, Felix , Else, Tobias , Hamidi, Oksana , Hulsteijn, Leonie T. van , Karavitaki, Niki , Prete, Alessandro , Vaidya, Anand , Yedinak, Christine, Bancos, Irina , Hamidi, Oksana , van Hulsteijn, Leonie , Karavitaki, Niki , Prete, Alessandro , Vaidya, Anand , Dekkers, Olaf M , Beuschlein, Felix , Bancos, Irina , Hahner, Stefanie , Husebye, Eystein Sverre , Dekkers, Olaf M.

Mayo Clinic

European Journal of Endocrinology | March 19, 2024 | Volume: 190 | Issue: 5 | Pages: G25-G51

10.1093/ejendo/lvae029 | PMID 38714321 Get It

Abstract Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy, being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility. Once glucocorticoid-induced adrenal insufficiency develops or is suspected, it necessitates careful education and management of affected patients. Tapering glucocorticoids can be challenging when symptoms of glucocorticoid withdrawal develop, which overlap with those of adrenal insufficiency. In general, tapering of glucocorticoids can be more rapidly within a supraphysiological range, followed by a slower taper when on physiological glucocorticoid dosing. The degree and persistence of HPA axis suppression after cessation of glucocorticoid therapy are dependent on overall exposure and recovery of adrenal function varies greatly amongst individuals. This first European Society of Endocrinology/Endocrine Society joint clinical practice guideline provides guidance on this clinically relevant condition to aid clinicians involved in the care of patients on chronic glucocorticoid therapy.
Sexual Medicine Society of North America (SMSNA)/American Urological Association (AUA) telemedicine and men’s health white paper
Khera, Mohit , Bernie, Helen L. , Carrier, Serge , Faraday, Martha M., Köhler, Tobias , Jenkins, Lawrence C. , Watter, Daniel N., Mulhall, John P. , Rubin, Rachel , Spitz, Aaron, Yafi, Faysal A. , Sadeghi‐Nejad, Hossein , Broderick, Gregory, Jenkins, Lawrence , Broderick, Gregory A. , Raheem, Omer A. , Ramasamy, Ranjith

Mayo Clinic

The Journal of Sexual Medicine | March 2, 2024 | Volume: 21 | Issue: 4 | Pages: 318-332

10.1093/jsxmed/qdad151 | PMID 38430132 Get It

Abstract Purpose The purpose of this white paper is to educate health care professionals about the evolution of telemedicine (TM) and to propose a hybrid model that leverages the strengths of traditional in-person medicine as well as virtual medicine while maximizing the safety and quality of men’s sexual health care. Literature Search Strategy A literature search focused on the use of TM in urology and men’s health was performed through PubMed/MEDLINE, Embase, and Web of Science (January 1, 2012–April 26, 2022). Keywords included all known permutations of the terminology used to refer to virtual health, care as well as the terminology used to refer to urologic diseases, issues specific to men’s health, and men’s sexual health concerns. Publications that emerged after the literature search that met this criterion also were incorporated. Opinion pieces, letters to the editor, meeting abstracts, and conference proceedings were excluded. Additional resources were retrieved, such as governmental technical reports, legislative updates and reviews, and blogs. This search strategy yielded 1684 records across databases after removal of duplicates. Abstracts from the retrieved records were reviewed for relevance. Relevant publications were defined as those that reported data on any aspect of TM use specific to urology, men’s health, and/or men’s sexual health. If relevance was unclear from the abstract, then the full text of the article was retrieved for a more detailed review. In addition, the published evidence-based practice guidelines relevant to care for erectile dysfunction, Peyronie’s disease, ejaculatory dysfunction, and hypogonadism were retrieved. The most common reasons for article exclusions were a focus on TM use in disciplines other than urology and the absence of data (ie, opinion pieces). After exclusions, a total of 91 publications remained and constituted the evidence base for this paper.